Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16288777 | 0.89 | HDAC1 (0.38) | HDAC1HDAC6CTSBCTSLCTSS | |
| SCHEMBL15083394 | 0.89 | HDAC1 (0.38) | HDAC1HDAC6CTSBCTSLCTSS | |
| SCHEMBL7074223 | 0.89 | ACE (0.47) | HDAC1HDAC6CTSBTACR1CTSL | |
| SCHEMBL7074221 | 0.89 | ACE (0.47) | HDAC1HDAC6CTSBTACR1CTSL | |
| SCHEMBL16288907 | 0.86 | NOS3 (0.42) | HDAC1HDAC6TACR1CTSL | |
| SCHEMBL15083531 | 0.86 | NOS3 (0.42) | HDAC1HDAC6TACR1CTSL | |
| SCHEMBL22686106 | 0.85 | CTSS (0.48) | ALDH1A1CTSBTACR1CTSLCTSS | |
| SCHEMBL20630581 | 0.82 | CTSL (0.46) | CTSBCTSLCTSS | |
| SCHEMBL22348905 | 0.82 | CTSS (0.45) | ATMALDH1A1CTSBTACR1CTSL | |
| SCHEMBL22686097 | 0.82 | CTSS (0.45) | ATMALDH1A1CTSBTACR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | HDAC1 2622/4885HDAC6 337/4885ATM 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.